Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- The approval of non-qualified stock options demonstrates the company's commitment to attracting top talent and incentivizing new employees.
- The inducement grants being subject to a four-year vesting period aligns with industry standards and incentivizes employee retention.
- None.
The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About Viridian Therapeutics
Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting its first global Phase 3 trial called ‘THRIVE’ to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also planning a second Phase 3 trial, called THRIVE-2, to evaluate the safety and efficacy of VRDN-001 in patients with chronic TED. In addition to its program for intravenously administered VRDN-001, the Company is advancing three candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is also developing multiple preclinical assets in autoimmune and rare diseases.
Viridian is based in
Source: Viridian Therapeutics, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230804547612/en/
Investors:
Todd James, 617-272-4691
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com
Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com
Media:
Matt Fearer, 617-272-4605
Vice President, Corporate Communications
Media@viridiantherapeutics.com
Source: Viridian Therapeutics, Inc.
FAQ
What is the significance of the announcement by Viridian Therapeutics, Inc. (Nasdaq: VRDN)?
How many shares were granted to the new employees?
What is the vesting period for the Inducement Grants?